ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 32

Risk for Lung Cancer in RA and Different RA Phenotypes: Results from a Population-Based Case-Control Study

Katerina Chatzidionysiou1, Gudrun Reynisdottir2, Vijay Joshua2, Thomas Frisell3, Johan Askling3 and Anca I Catrina2, 1Department of Medicine, Unit of Rheumatology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 2Unit of Rheumatology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 3Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Lung Disease and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: It has been shown that patients with Rheumatoid Arthritis (RA) are at increased risk for certain malignancies, among them lung cancer. We aimed to investigate the association between lung cancer and different RA phenotypes based on rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA) status.

Methods: We used the population-based case-control study EIRA (Epidemiological Investigation of Risk factors for Rheumatoid Arthritis). Patients with RA diagnosis and controls (matched for age, sex, calendar period and area of residence) were included during 1996-2013.  The data were linked to the Swedish nationwide cancer register. Cox regression was used to calculate RR. Due to the significant correlation between smoking and RA as well as presence of RF and ACPA, stratified analyses based on smoking status were performed, in order to account for effect modification.

Results: A total of 3547 RA patients and 5586 controls were included in the study.  The mean age (SD) was 52 (13) years and the percentage of female was 72%. Significantly more RA patients than controls were diagnosed with lung cancer after RA diagnosis (58 vs. 26 per 100,000 patient-years, respectively, p=0.002). RA itself gave twice an increased risk for developing lung cancer when adjusted for age and sex (RR=1.9, 95% CI=1.2-3.2, p=0.01), but the statistical significance disappeared when smoking was included in the model. However, after stratification according to smoking status, RA was significantly associated to lung cancer development in never or ex-smokers (RR=2.4, 95% CI=1.0-6.2, p=0.05) but not in current smokers (RR=1.2, 95% CI=0.6-2.3, p=0.6).

In RA patients, higher age, smoking, RF positivity, RF and/or ACPA positivity and double seropositivity were significant risk factors for lung cancer (table 1). In a stratified by smoking status analysis RF positivity was significantly associated to lung cancer in non-smokers (table 2).

Conclusion: In this study RA, especially RF positive RA, was associated to the development of lung cancer in never or ex-smokers. Although not statistically significant, patients who developed lung cancer were more often positive for RF and/or ACPA irrespective of smoking status.


Disclosure: K. Chatzidionysiou, None; G. Reynisdottir, None; V. Joshua, None; T. Frisell, None; J. Askling, None; A. I. Catrina, None.

To cite this abstract in AMA style:

Chatzidionysiou K, Reynisdottir G, Joshua V, Frisell T, Askling J, Catrina AI. Risk for Lung Cancer in RA and Different RA Phenotypes: Results from a Population-Based Case-Control Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/risk-for-lung-cancer-in-ra-and-different-ra-phenotypes-results-from-a-population-based-case-control-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-for-lung-cancer-in-ra-and-different-ra-phenotypes-results-from-a-population-based-case-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology